Business Trip

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center.  She is the Director at the Mental Health Patient Care Center a...

In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical , a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources. In...

In today’s episode, we chat with Lucia Huang , the CEO and co-founder of Osmind , an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics.  In this episode, we discuss: How Osmind makes data-driven decisions  Osmind’s quick growth in only 2 years What it will take for insurance to cover ketamine therapy, as well as other psych...

In today’s episode, we chat with Tim Schlidt , a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis , Tactogen , and Journey Clinical . In this episode, we discuss: Tim’s background in healthcare finance Investing in classic psychedelic compounds vs. 2nd generation compounds Hallmarks of a good first meeting wit...

Today’s episode features Dillan Dinardo and Tom Ray , the co-founders of Mindstate Design Labs . Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round. In this episode, we discuss: Tom and Dillan’s experience in YC...

Today’s episode features Amy Emerson , the CEO of MAPS Public Benefit Corporation (PBC) , which is a fully owned subsidiary of MAPS , and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy. In this episode, we discuss: MAPS’ protocol and strategy behind FDA clinical trial for PTSD Amy’s views on the state of the industry...

In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health , an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and...

In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech...

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways , a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression. In this episode, we discuss: Lars’ experience overcoming Treatment-Resistant Depression with psilocybin The nuances of clinical trials and psilocybin dosing protocols Compass Pathways’ Intellectual Proper...

Today's episode features three experts, Josh Hardman , Michael Haichin , and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO.  In this episode, we discuss: How atai went from idea to IPO in 3 years An overview of atai’s drug development programs and enabling technologies The platform’s strategy and risks Links to topics in this episode: Atai life sciences Etifoxine Esketami...

Today's episode features Deborah Mash , founder and CEO of DemeRx , a clinical stage company developing ibogaine therapies to treat substance use disorders. In this episode, we discuss: The science, experience and the safety behind Ibogaine’s “neurochemical reset” Navigating US drug regulatory system and securing Intellectual Property Deborah’s 30 journey through Amsterdam, Miami and the Cari...

Today's episode features Zach Haigney , creator of The Trip Report , a newsletter about psychedelics, policy and business. In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness. In this episode, we discuss: Origin story of The Trip Repo...

Today's episode features Danny Motyka , founder of Psygen , a Canadian manufacturer of psychedelics, like MDMA, LSD, DMT, and synthetic psilocybin. Psygen makes pharmaceutical grade psychedelic medicines for clinical research and therapeutic applications. They have a license to be one of the first manufacturing facilities dedicated to the synthesis of psychedelic medicine.  In this episode, w...

Today's episode features Flor Bollini, founder of NANA , an online platform that guides patients on using psychedelic medicine for holistic healing. NANA provides personalized protocols based on an assessment of your mental, emotional and physical health. From there you are partnered with a Nana or guide who leads telemedicine therapy that incorporates ketamine, cannabis and CBD. Flor hopes t...

Today's episode features David Champion, CEO and co-founder of Maya , a software platform that helps practitioners and clinics manage psychedelic-assisted therapy practices. The data collected from treatments will help psychedelic stakeholders, from researchers to pharmaceutical companies, discover insights for safer and more effective treatments. In this episode, we discuss: Removing the gue...

Today's episode features Ryan Zurrer, founder of Vine Ventures , one of the first venture capital funds investing in psychedelic medicine. Ryan has deep roots in psychedelics culture and understands the many cultures within the psychedelic space. His fund is aligned with those values. If you’re a founder, investor, or early hire at a psychedelic company, this episode is a must-listen! In this...

Today’s episode features Shelby Hartman and Madison Margolin from DoubleBlind , a psychedelic magazine and media company founded in 2019 covering timely, untold stories about the expansion of psychedelics around the globe. Focused on how the industry can engage in sacred reciprocity and ethical psychedelic therapies, DoubleBlind is a for-profit company working on becoming a fully licensed certifie...

Today’s episode features Dylan Beynon from Mindbloom , a mental and wellbeing startup that is currently offering ketamine-assisted therapy to treat anxiety and depression. Mindbloom is opening clinics across the country and is using technology to lower the cost of treatment. Host Greg Kubin participates in a ketamine-assisted therapy session in the episode. And that ethereal track you hear during...